

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of Illinois may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSIL has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Venous and Arterial Thrombosis Risk Testing

Policy Number: CPCPLAB058

Version 1.0

Approval Date: September 5, 2025

Plan Effective Date: January 1, 2026

Description

The Plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information

1. For individuals without recurrent venous thromboembolism/VTE risk factors (e.g., surgery, prolonged immobilization, collagen vascular disease, malignancy, certain hematologic disorders), plasma testing for protein C deficiency, protein S deficiency, and antithrombin III deficiency (See **Notes 1 and 2**) **may be reimbursable** in any of the following situations:
 - a. For individuals less than 50 year of age who have experienced any deep venous thrombosis/DVT.
 - b. For individuals who have experienced a DVT in unusual sites (e.g., hepatic, mesenteric, or cerebral veins).
 - c. For individuals who have experienced a DVT and who have a strong family history of thrombotic disease.
 - d. For individuals who are pregnant or taking oral contraceptives and who have experienced a DVT.
 - e. For first-and second-degree relatives (See **Note 2**) of individuals who have experienced a deep venous thrombosis before 50 years of age.
 - f. For women under the age of 50 who smoke and who have suffered a Myocardial infarction.
 - g. Before the administration of oral contraceptives, targeted testing of individuals with a personal or family history of DVT.
 - h. For pediatric individuals who have suffered from a pediatric arterial ischemic stroke.
2. For individuals with warfarin-induced skin necrosis or for infants who develop neonatal purpura fulminans, plasma testing for protein C deficiency and protein S deficiency (see **Note 1**) **may be reimbursable**.
3. Venous thrombosis risk testing for superficial venous thrombosis (including superficial thrombophlebitis and varicosities) **is not reimbursable**.
4. For all situations, all activated protein C/aPC resistance assay **is not reimbursable**.
5. DVT risk testing as part of a pre-transplant evaluation test **is not reimbursable**.

Note 1: Plasma testing for protein C deficiency, protein S deficiency and antithrombin III deficiency should be performed at least six weeks after the acute thrombotic event and while the patient is not taking anticoagulants. Assays for clotting inhibitors amount and function should be performed prior to any molecular testing.

Note 2: In addition to plasma testing (protein C deficiency, protein S deficiency, antithrombin III deficiency), risk factor testing for individuals suspected of having a hereditary and/or acquired thrombophilia should include genetic testing for Factor V Leiden and Prothrombin gene G20210A mutations.

Note 3: First-degree relatives include parents, full siblings, and children of the individual. Second-degree relatives include grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings of the individual.

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
85300, 85301, 85302, 85303, 85305, 85306, 85307

References

1. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. *J Thromb Thrombolysis*. 2016;41:154-64. doi:10.1007/s11239-015-1316-1
2. Bartholomew JR. Update on the management of venous thromboembolism. *Cleveland Clinic journal of medicine*. Dec 2017;84(12 Suppl 3):39-46. doi:10.3949/ccjm.84.s3.04
3. Herrmann J. *Clinical Cardio-Oncology*. Elsevier; 2018.
4. Bauer K, Lip G. Overview of the causes of venous thrombosis. Updated February 27, 2025. <https://www.uptodate.com/contents/overview-of-the-causes-of-venous-thrombosis>
5. Byrnes JR, Wolberg AS. Red blood cells in thrombosis. *Blood*. Oct 19 2017;130(16):1795-1799. doi:10.1182/blood-2017-03-745349
6. Bauer K. Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity. Updated February 27, 2025. <https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-deep-vein-thrombosis-of-the-lower-extremity>
7. Thompson BT, Kabrhel, Christopher. Overview of acute pulmonary embolism in adults. Updated February 27, 2025. <https://www.uptodate.com/contents/overview-of-acute-pulmonary-embolism-in-adults>

8. Crous-Bou M, Harrington LB, Kabrhel C. Environmental and genetic risk factors associated with venous thromboembolism. *Semin Thromb Hemost.* Nov 2016;42(8):808-20. doi:10.1055/s-0036-1592333
9. Bauer K. Factor V Leiden and activated protein C resistance. Updated November 20, 2024. <https://www.uptodate.com/contents/factor-v-leiden-and-activated-protein-c-resistance>
10. Bauer K. Protein S deficiency. Updated March 05, 2024. <https://www.uptodate.com/contents/protein-s-deficiency>
11. Bauer K. Prothrombin G20210A mutation. Updated February 28, 2023. <https://www.uptodate.com/contents/prothrombin-g20210a-mutation>
12. Bauer K. Protein C deficiency. Updated February 25, 2025. <https://www.uptodate.com/contents/protein-c-deficiency>
13. Connors JM. Thrombophilia Testing and Venous Thrombosis. *N Engl J Med.* 2017;377(23):2298. doi:10.1056/NEJMc1713797
14. Bauer K, Lip G. Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors. Updated May 18, 2023. <https://www.uptodate.com/contents/evaluating-adult-patients-with-established-venous-thromboembolism-for-acquired-and-inherited-risk-factors>
15. Kujovich JL. Factor V Leiden thrombophilia. *Genet Med.* Jan 2011;13(1):1-16. doi:10.1097/GIM.0b013e3181faa0f2
16. Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test? *Vasc Med.* Aug 2018;23(4):388-399. doi:10.1177/1358863x18755927
17. Kujovich JL. Factor V Leiden Thrombophilia. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. *GeneReviews((R))*. University of Washington, Seattle; 2018.
18. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. *Blood Transfus.* Apr 2011;9(2):120-38. doi:10.2450/2010.0066-10
19. NATF. Genetic Risk Factors for Blood Clots and the Role of Genetic Testing. <https://natfonline.org/2019/01/genetic-risk-factors-blood-clots-role-genetic-testing/>
20. Raffini L, Mahoney DH, Armsby C. Thrombophilia testing in children and adolescents. <https://www.uptodate.com/contents/thrombophilia-testing-in-children-and-adolescents>
21. Curtis C, Mineyko A, Massicotte P, et al. Thrombophilia risk is not increased in children after perinatal stroke. *Blood.* May 18 2017;129(20):2793-2800. doi:10.1182/blood-2016-11-750893
22. Ferriero DM, Fullerton HJ, Bernard TJ, et al. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. *Stroke.* 2019;50(3)doi:10.1161/str.0000000000000183
23. Lehman LL, Beaute J, Kapur K, et al. Workup for Perinatal Stroke Does Not Predict Recurrence. *Stroke.* 2017;48(8):2078-2083. doi:10.1161/STROKEAHA.117.017356
24. Middeldrop S. Lab Interpretation: Positive factor V Leiden or abnormal activated protein C resistance in adults. Updated 10/28/2021. <https://www.uptodate.com/contents/factor-v-leiden-and-activated-protein-c-resistance>

25. de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. *Br J Haematol*. Jul 2000;110(1):125-9. doi:10.1046/j.1365-2141.2000.02039.x
26. Mäkelburg AB, Veeger NJ, Middeldorp S, et al. Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. *Haematologica*. Jun 2010;95(6):1030-3. doi:10.3324/haematol.2009.017061
27. Murphy CH, Sabath DE. Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden. *Am J Clin Pathol*. Feb 4 2019;151(3):302-305. doi:10.1093/ajcp/aqy142
28. Chiasakul T, De Jesus E, Tong J, et al. Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. Oct 2019;8(19):e012877. doi:10.1161/jaha.119.012877
29. Ordieres-Ortega L, Demelo-Rodríguez P, Galeano-Valle F, Kremers BMM, ten Cate-Hoek AJ, ten Cate H. Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review. *Thrombosis Research*. 2020/05/01/ 2020;189:5-12. doi:10.1016/j.thromres.2020.02.009
30. Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly. *Int J Lab Hematol*. May 2017;39 Suppl 1:98-103. doi:10.1111/ijlh.12665
31. Algahtani FH, Stuckey R. High factor VIII levels and arterial thrombosis: illustrative case and literature review. *Ther Adv Hematol*. 2019;10:2040620719886685. doi:10.1177/2040620719886685
32. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. *J Thromb Haemost*. Jan 2005;3(1):79-84. doi:10.1111/j.1538-7836.2004.01033.x
33. Lee EJ, Dykas DJ, Leavitt AD, et al. Whole-exome sequencing in evaluation of patients with venous thromboembolism. *Blood advances*. Jul 11 2017;1(16):1224-1237. doi:10.1182/bloodadvances.2017005249
34. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of genetic testing in adults with a history of venous thromboembolism. *Evidence report/technology assessment*. Jun 2009;(180):1-162.
35. Onda S, Furukawa K, Haruki K, et al. d-dimer-based screening for early diagnosis of venous thromboembolism after hepatectomy. *Langenbeck's Archives of Surgery*. 2021/05/01 2021;406(3):883-892. doi:10.1007/s00423-020-02058-9
36. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke*. Jul 2021;52(7):e364-e467. doi:10.1161/str.0000000000000375
37. Zhang S, Taylor AK, Huang X, et al. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. Dec 2018;20(12):1489-1498. doi:10.1038/s41436-018-0322-z
38. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. *Genet Med*. Feb 2013;15(2):153-6. doi:10.1038/gim.2012.165

39. Bashford MT, Hickey SE, Curry CJ, et al. Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. *Genetics in Medicine*. 2020/12/01 2020;22(12):2125-2125. doi:10.1038/s41436-020-0843-0
40. ASH. ASH - Testing for thromboembolism | Choosing Wisely. Choosing Wisely <https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely>
41. Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. *Blood advances*. 2018;2(22):3226. doi:10.1182/bloodadvances.2018024828
42. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. *Blood advances*. 2020;4(19):4693-4738. doi:10.1182/bloodadvances.2020001830
43. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. *Blood advances*. Nov 28 2023;7(22):7101-7138. doi:10.1182/bloodadvances.2023010177
44. ACOG. ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. *Obstetrics and gynecology*. Sep 2013;122(3):706-17. doi:10.1097/01.AOG.0000433981.36184.4e
45. ACOG. ACOG Practice Bulletin No. 197 Summary: Inherited Thrombophilias in Pregnancy. *Obstetrics and gynecology*. Jul 2018;132(1):249-251. doi:10.1097/aog.0000000000002705
46. EGAPP. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. *Genet Med*. Jan 2011;13(1):67-76. doi:10.1097/GIM.0b013e3181fbc46f
47. Gupta A, Sarode R, Nagalla S. Thrombophilia Testing in Provoked Venous Thromboembolism: A Teachable Moment. *JAMA Internal Medicine*. 2017;177(8):1195-1196. doi:10.1001/jamainternmed.2017.1815
48. Barnes G. Thrombophilia Testing for Provoked VTE. American College of Cardiology. Updated 06/05/2017. Accessed 02/13/2019, 2019. <https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/06/05/12/46/thrombophilia-testing-in-provoked-venous-thromboembolism>
49. Barnes GD. Thrombophilia Testing and Venous Thrombosis. American College of Cardiology. <https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/10/20/11/18/thrombophilia-testing-and-venous-thrombosis>.
50. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Respir J*. Sep 2019;54(3)doi:10.1183/13993003.01647-2019

51. Mazzolai L, Ageno W, Alatri A, et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. *European Journal of Preventive Cardiology*. 2022;doi:10.1093/eurjpc/zwab088
52. WHO. Medical eligibility criteria for contraceptive use.
<https://www.who.int/publications/i/item/9789241549158>
53. NICE. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing.
<https://www.nice.org.uk/guidance/ng158/chapter/Recommendations#thrombophilia-testing>
54. Kirsch J, Wu CC, Bolen MA, et al. ACR Appropriateness Criteria® Suspected Pulmonary Embolism: 2022 Update. *J Am Coll Radiol*. Nov 2022;19(11s):S488-S501. doi:10.1016/j.jacr.2022.09.014
55. Thrombosis Canada. Pulmonary Embolism (PE): Diagnosis.
https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=PULMONARYEMBOLISMDIAGNOSISANDM

Policy Update History

Approval Date	Effective Date; Summary of Changes
09/05/2025	01/01/2026: New policy.